Dexnaaf 60 

Presentation: Dexnaaf 60 Capsule, available in Bangladesh, contains Dexlansoprazole 60 mg. It is presented as delayed-release capsules for oral administration, usually available in blister packs. The capsule contains enteric-coated granules with a dual delayed-release mechanism.

Indications: Dexnaaf (Dexlansoprazole) is indicated for:

• Healing of all grades of erosive esophagitis (EE) for up to 8 weeks.
• Maintaining healing of EE and relieving heartburn for up to 6 months.
• Treatment of heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD) for 4 weeks.  

Dosage and Administration:   Dexnaaf 60 capsules should be swallowed whole and can be taken without regard to food. Alternatively, the capsule can be opened, and the intact granules can be sprinkled on one tablespoon of applesauce and swallowed immediately. The granules should not be chewed.

• Healing of erosive esophagitis:60 mg once daily for up to 8 weeks.  
• Maintenance of healed erosive esophagitis and relief of heartburn:30 mg once daily for up to 6 months.  
• Symptomatic non-erosive GERD:30 mg once daily for4 weeks.

If a dose is missed, it should be taken as soon as possible. If it is too close to the time of the next dose, only the prescribed dose should be taken at the appointed time. A double dose should not be taken.  

SideEffects: Common side effects of Dexnaaf (Dexlansoprazole) may include:

• Diarrhea
• Abdominal pain
• Nausea
• Vomiting
• Flatulence

Less common but potentially serious side effects can occur. It is important to consult your doctor if you experience any unusual symptoms, especially severe diarrhea, symptoms of low magnesium levels (such as seizures, dizziness, or abnormal heart rate), signs of vitamin B12 deficiency, new or worsening symptoms of lupus, or kidney problems.

Precautions: Dexnaaf (Dexlansoprazole) is contraindicated in patients with known hypersensitivity to any component of the formulation.

Caution should be exercised in patients with:

• Severe liver disease.
• Low levels of calcium, magnesium, or potassium in the blood.
• Lupus.
• A history of bone fractures or risk factors for osteoporosis.

Long-term use of Dexlansoprazole may increase the risk of bone fractures, low magnesium levels, and vitamin B12 deficiency. It may also increase the risk of Clostridium difficile-associated diarrhea. Gastric malignancy should be ruled out before initiating therapy. Inform your doctor about all other medications you are taking, as Dexlansoprazole can interact with certain drugs.

Use in Pregnancy and Breastfeeding: There are no adequate and well-controlled studies on the use of Dexlansoprazole in pregnant or breastfeeding women. It should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not known whetherDexlansoprazole is excreted in human milk. A decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importanceof the drug to the mother.  

Storage:   Store below 30°C in a dry place, protected from light. Keep all medicines out of reach of children.

Important Note: This information is for general knowledge and informational purposes only, and does not substitute professional medical advice. Always consult your doctor or pharmacist for specific instructions and guidance regarding your medication. They can assess your individual medical condition and provide the most appropriate advice.